Shen S, Jiang L, Xiao GQ, Yan LN, Yang JY, Wen TF, Li B, Wang WT, Xu MQ, Wei YG. Prophylaxis against hepatitis B virus recurrence after liver transplantation: A registry study. World J Gastroenterol 2015; 21(2): 584-592 [PMID: 25593480 DOI: 10.3748/wjg.v21.i2.584]
Corresponding Author of This Article
Li Jiang, MD, Liver Transplantation Center, Department of Liver Surgery, West China Hospital of Sichuan University, No. 37 Guoxuexiang Road, Chengdu 610041, Sichuan Province, China. jiangli029@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 14, 2015; 21(2): 584-592 Published online Jan 14, 2015. doi: 10.3748/wjg.v21.i2.584
Prophylaxis against hepatitis B virus recurrence after liver transplantation: A registry study
Shu Shen, Li Jiang, Guang-Qin Xiao, Lu-Nan Yan, Jia-Yin Yang, Tian-Fu Wen, Bo Li, Wen-Tao Wang, Ming-Qing Xu, Yong-Gang Wei
Shu Shen, Li Jiang, Guang-Qin Xiao, Lu-Nan Yan, Jia-Yin Yang, Tian-Fu Wen, Bo Li, Wen-Tao Wang, Ming-Qing Xu, Yong-Gang Wei, Liver Transplantation Center, Department of Liver Surgery, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Shen S and Jiang L contributed equally to this study; Jiang L, Wen TF, Yan LN and Li B introduced the idea and designed the work; Yang JY, Wang WT and Wei YG analyzed the data; Shen S drafted the article; Jiang L and Xiao GQ revised the article; and Yang JY approved the version to be published.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Li Jiang, MD, Liver Transplantation Center, Department of Liver Surgery, West China Hospital of Sichuan University, No. 37 Guoxuexiang Road, Chengdu 610041, Sichuan Province, China. jiangli029@163.com
Telephone: +86-28-85422871 Fax: +86-28-85422871
Received: May 19, 2014 Peer-review started: May 20, 2014 First decision: June 27, 2014 Revised: August 4, 2014 Accepted: November 11, 2014 Article in press: November 11, 2014 Published online: January 14, 2015
Core Tip
Core tip: Little is known about which protocol has the optimal prophylactic effects against hepatitis B virus (HBV) recurrence. In this study, we used data from the China Liver Transplant Registry database to evaluate the long-term prophylactic efficacy of hepatitis B immunoglobulin (HBIG) in combination with different nucleos(t)ide analogues and determine the risk factors for HBV recurrence. This nationwide multicenter study demonstrated that low-dose intramuscular HBIG in combination with a nucleos(t)ide analogue provides effective prophylaxis against recurrent HBV infection posttransplantation at approximately 5% of the cost of conventional high-dose intravenous HBIG regimens. Among them, low-dose intramuscular HBIG combined with entecavir has better prophylactic efficacy than the combination of low-dose intramuscular HBIG and lamivudine.
